428 related articles for article (PubMed ID: 32841270)
21. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
[TBL] [Abstract][Full Text] [Related]
22. Choroidal metastasis from papillary thyroid cancer: An unusual feature of a common disease.
Fountas A; Tigas S; Giotaki Z; Tsatsoulis A; Kalogeropoulos CD
Ann Endocrinol (Paris); 2017 Feb; 78(1):64-66. PubMed ID: 27887671
[No Abstract] [Full Text] [Related]
23. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Weng HF; Lu WT; Huang MJ
Eur J Nucl Med; 1998 Jul; 25(7):695-700. PubMed ID: 9662590
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
25. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
[TBL] [Abstract][Full Text] [Related]
27. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
29. Rare metastases of well-differentiated thyroid cancers: a systematic review.
Madani A; Jozaghi Y; Tabah R; How J; Mitmaker E
Ann Surg Oncol; 2015 Feb; 22(2):460-6. PubMed ID: 25192681
[TBL] [Abstract][Full Text] [Related]
30. Clinical Status and Treatment of Liver Metastasis of Differentiated Thyroid Cancer Using Tyrosine Kinase Inhibitors.
Saito Y; Sugino K; Takami H; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Kawakubo H; Ito K; Kitagawa Y
World J Surg; 2018 Nov; 42(11):3632-3637. PubMed ID: 29766229
[TBL] [Abstract][Full Text] [Related]
31. Prolonged duration of response in lenvatinib responders with thyroid cancer.
Gianoukakis AG; Dutcus CE; Batty N; Guo M; Baig M
Endocr Relat Cancer; 2018 Jun; 25(6):699-704. PubMed ID: 29752332
[TBL] [Abstract][Full Text] [Related]
32. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?
Giammarile F; Hafdi Z; Bournaud C; Janier M; Houzard C; Desuzinges C; Itti R; Sassolas G; Borson-Chazot F
Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343
[TBL] [Abstract][Full Text] [Related]
33. Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.
Werner RA; Lückerath K; Schmid JS; Higuchi T; Kreissl MC; Grelle I; Reiners C; Buck AK; Lapa C
Sci Rep; 2016 Jun; 6():28081. PubMed ID: 27306607
[TBL] [Abstract][Full Text] [Related]
34. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
35. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
36. Approach to the thyroid cancer patient with extracervical metastases.
Haugen BR; Kane MA
J Clin Endocrinol Metab; 2010 Mar; 95(3):987-93. PubMed ID: 20203334
[TBL] [Abstract][Full Text] [Related]
37. Improved Survival After Multimodal Approach with
Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
[No Abstract] [Full Text] [Related]
38. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome.
Lin JD; Hsueh C; Chao TC
Thyroid; 2009 Oct; 19(10):1053-9. PubMed ID: 19772423
[TBL] [Abstract][Full Text] [Related]
39. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]